French multicentre double-blind study to evaluate the efficacy and safety of acrivastine as compared with terfenadine in seasonal allergic rhinitis.

In this double-blind, multicentre study the antihistamine acrivastine was compared with terfenadine for the treatment of seasonal allergic rhinitis. The study was divided into three periods which together lasted 56 days. Patients (n = 83) were randomly assigned treatment with either 8 mg acrivastine three times daily or 60 mg terfenadine twice daily.

[Immuno-allergological study on 30 atopic patients (author's transl)].

An immuno-allergological study was performed on 30 atopic patients and the data were compared to those of 30 healthy controls. The findings were: --increased level of IgE class immunoglobulins in the atopic patients; --increased frequency of the presence of specific reagin to numerous allergens in the sera of atopics (RAST). The total amount of IgE was related to the presence of numerous and/or strongly positive RAST; --immediate hypersensitivity reaction (IHR) to various allergens and specially house-dust.